Generic medicines manufacturers ramp up patch supply to meet demand
AAM highlights essential role generics manufacturers play in supplying estrogen patches; notes the complexity of its production and reasons for not declaring a nationwide shortage
AAM highlights essential role generics manufacturers play in supplying estrogen patches; notes the complexity of its production and reasons for not declaring a nationwide shortage
Generics and biosimilars represented 89% of U.S. prescriptions but only 12% of prescription drug spending in 2025, according to AAM.
New plan phases in tariffs of 100% in 2028 and 200% in 2029 as manufacturers weigh the cost of shifting production to the U.S.
“The first-to-market launch underscores our capabilities in bringing store-brand equivalents of leading OTC brands to the U.S. market.”
The webinar offers valuable insights into the business and policy dynamics that shape the future of generic medications.
Join for an insightful webcast that delves into the vital role of generic medications in our healthcare system.